{"id":3738,"date":"2026-10-09T14:46:46","date_gmt":"2026-10-09T14:46:46","guid":{"rendered":"https:\/\/nhdbio.com\/?p=3738"},"modified":"2026-10-10T07:26:15","modified_gmt":"2026-10-10T07:26:15","slug":"eloratzp-amilina-tirzepatida-fase2b-resultados-explicados","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/","title":{"rendered":"EloraTZP: Por que pesquisadores est\u00e3o combinando amilina e tirzepatida"},"content":{"rendered":"

O que acontece quando os pesquisadores adicionam outro sinal relacionado \u00e0 saciedade a um tratamento com incretina? EloraTZP \u00e9 uma tentativa de responder a essa pergunta. Seus resultados iniciais s\u00e3o encorajadores, mas os achados de tolerabilidade merecem igual aten\u00e7\u00e3o.<\/p>\n

O que foi testado?<\/h2>\n

A Lilly anunciou resultados de fase 2b em 30 de setembro de 2026 em 367 adultos com sobrepeso ou obesidade e diabetes tipo 2. EloraTZP combina eloralintida, um agonista seletivo do receptor de amilina, com tirzepatida, um agonista duplo dos receptores GIP\/GLP-1. O estudo durou 48 semanas.<\/p>\n\n\n\n\n\n\n\n
Bra\u00e7o relatado<\/th>\nRedu\u00e7\u00e3o m\u00e9dia de peso, estimando de efic\u00e1cia<\/th>\nRedu\u00e7\u00e3o de HbA1c<\/th>\n<\/tr>\n<\/thead>\n
Maior combina\u00e7\u00e3o EloraTZP relatada<\/td>\n23.3%<\/td>\n2.9 pontos percentuais<\/td>\n<\/tr>\n
Tirzepatida 15 mg<\/td>\n14.8%<\/td>\n2.4 pontos percentuais<\/td>\n<\/tr>\n
Placebo<\/td>\n3.0%<\/td>\n0.3 pontos percentuais<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A compara\u00e7\u00e3o prim\u00e1ria foi combina\u00e7\u00e3o versus placebo; outras compara\u00e7\u00f5es foram secund\u00e1rias. As descontinua\u00e7\u00f5es no bra\u00e7o de combina\u00e7\u00e3o devido a eventos adversos variaram de 10.8% a 27.0%, em compara\u00e7\u00e3o com 2.9% para tirzepatida. Eventos gastrointestinais foram mais frequentes nos bra\u00e7os de combina\u00e7\u00e3o.<\/p>\n

Os participantes receberam os dois componentes separadamente. Um produto coformulado de fase 3 foi planejado, n\u00e3o testado neste estudo de fase 2b. A combina\u00e7\u00e3o permaneceu em investiga\u00e7\u00e3o.<\/p>\n

Por que adicionar um sinal de amilina?<\/h2>\n

The research question is whether engaging another appetite-related pathway adds a useful effect. \u201cMore pathways\u201d should not be treated as a guarantee of a better overall outcome. An additional mechanism can bring additional questions about tolerability, formulation and how an effect changes over time.<\/p>\n

Para um leitor novo no tema, a distin\u00e7\u00e3o importante \u00e9 entre os nomes dos componentes e a combina\u00e7\u00e3o em si. Um estudo de dois componentes juntos n\u00e3o \u00e9 automaticamente evid\u00eancia para qualquer um dos componentes isoladamente.<\/p>\n

Leia benef\u00edcio e tolerabilidade em conjunto<\/h2>\n

A maior redu\u00e7\u00e3o de peso relatada \u00e9 uma m\u00e9dia de grupo de uma an\u00e1lise especificada. N\u00e3o \u00e9 o resultado alcan\u00e7ado por todos os participantes, nem uma previs\u00e3o para uma nova pessoa.<\/p>\n

Os n\u00fameros de descontinua\u00e7\u00e3o tamb\u00e9m importam. Um estudo n\u00e3o pode ser compreendido plenamente olhando apenas para as pessoas que conseguiram continuar o tratamento. Pergunte como a an\u00e1lise lida com os participantes que param e se os resultados permanecem semelhantes sob outra pergunta sobre o efeito do tratamento.<\/p>\n

O an\u00fancio fornece uma faixa entre os bra\u00e7os de combina\u00e7\u00e3o. Essa faixa n\u00e3o deve ser atribu\u00edda inteiramente ao bra\u00e7o de melhor desempenho sem um relat\u00f3rio espec\u00edfico por bra\u00e7o.<\/p>\n

Inje\u00e7\u00f5es separadas n\u00e3o s\u00e3o uma mistura pronta<\/h2>\n

Colocar dois nomes em um r\u00f3tulo n\u00e3o demonstra que uma prepara\u00e7\u00e3o corresponde a uma interven\u00e7\u00e3o de ensaio. Identidade, propor\u00e7\u00f5es, formula\u00e7\u00e3o e o sistema de administra\u00e7\u00e3o s\u00e3o quest\u00f5es separadas. Um futuro produto coformulado precisa de seu pr\u00f3prio desenvolvimento e evid\u00eancias.<\/p>\n

Isso tamb\u00e9m explica por que misturas de cat\u00e1logo n\u00e3o devem tomar emprestados n\u00fameros de desempenho de ensaios. Compartilhar nomes de componentes n\u00e3o estabelece intercambiabilidade.<\/p>\n

O que fortaleceria as evid\u00eancias?<\/h2>\n

Um relat\u00f3rio detalhado deve mostrar desfechos e eventos adversos para cada bra\u00e7o, incerteza em torno das estimativas, manejo de dados faltantes e as compara\u00e7\u00f5es estat\u00edsticas planejadas. Ensaios de fases posteriores podem ent\u00e3o testar se o sinal inicial se sustenta em um cen\u00e1rio maior e definido.<\/p>\n

At\u00e9 ent\u00e3o, este \u00e9 um desenvolvimento de pesquisa a acompanhar, e n\u00e3o uma base para afirmar que uma mistura de laborat\u00f3rio entrega o mesmo resultado cl\u00ednico.<\/p>\n

Materiais relacionados para pesquisa laboratorial<\/h2>\n

Veja Tirzepatida<\/a> para a fam\u00edlia de cat\u00e1logo de laborat\u00f3rio relacionada. Cagrilintida<\/a> \u00e9 um material de pesquisa diferente relacionado \u00e0 amilina; n\u00e3o \u00e9 eloralintide. Esses links n\u00e3o indicam que NHD fornece EloraTZP ou uma combina\u00e7\u00e3o equivalente a ensaio.<\/p>\n

Para uma consulta, informe o nome do material, a quantidade e o teste laboratorial planejado. Pergunte quais registros de identidade, pureza e outros registros anal\u00edticos est\u00e3o dispon\u00edveis para a variante selecionada. Solicite informa\u00e7\u00f5es do produto em NHD<\/a>.<\/p>\n

Os medicamentos usados nesses ensaios n\u00e3o s\u00e3o intercambi\u00e1veis com materiais de cat\u00e1logo NHD. Os achados dos ensaios n\u00e3o estabelecem efeitos cl\u00ednicos, equival\u00eancia de formula\u00e7\u00e3o ou a qualidade de um lote NHD.<\/p>\n

Leia mais<\/h2>\n

Explore a explica\u00e7\u00e3o de pesquisa relacionada<\/a>.<\/p>\n

Fonte e revis\u00e3o editorial<\/h2>\n

An\u00fancio da fase 2b da Lilly, 30 setembro 2026<\/a>. Acessado em 9 outubro 2026. Este artigo explica um an\u00fancio de empresa; n\u00e3o \u00e9 revis\u00e3o por pares independente. Verifica\u00e7\u00f5es de fonte e legibilidade assistidas por IA foram conclu\u00eddas antes da publica\u00e7\u00e3o.<\/p>\n

Os materiais de cat\u00e1logo NHD s\u00e3o para pesquisa, desenvolvimento e fabrica\u00e7\u00e3o em laborat\u00f3rio, n\u00e3o para uso humano ou veterin\u00e1rio. Este artigo n\u00e3o fornece instru\u00e7\u00f5es de tratamento ou dosagem.<\/p>","protected":false},"excerpt":{"rendered":"

A Lilly relatou um estudo de combina\u00e7\u00e3o de fase 2b de 48 semanas em 367 adultos com diabetes tipo 2. Entenda os resultados de peso, descontinua\u00e7\u00f5es e limites de formula\u00e7\u00e3o.<\/p>","protected":false},"author":1,"featured_media":3923,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370,320","pim_article_type":"Research news explained","pim_evidence_level":"Company-reported results; study-specific limitations retained","pim_reviewer":"Codex AI editorial","pim_reviewed_date":"2026-10-09","pim_editorial_note":"AI-assisted source and readability checks, not independent peer review.","pim_review_status":"reviewed","pim_review_reason":"Primary sources and corrections checked; study populations and limitations retained; product-family links and enquiry paths reviewed; plain-language edit completed.","pim_creation_method":"AI-assisted writing","pim_sources":"[]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-3738","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nEloraTZP: Why Researchers Are Combining Amylin and Tirzepatide<\/title>\n<meta name=\"description\" content=\"Lilly reported a 48-week phase 2b combination study in 367 adults with type 2 diabetes. Understand the weight results, discontinuations and formulation limits.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/eloratzp-amilina-tirzepatida-fase2b-resultados-explicados\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide\" \/>\n<meta property=\"og:description\" content=\"Lilly reported a 48-week phase 2b combination study in 367 adults with type 2 diabetes. Understand the weight results, discontinuations and formulation limits.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/eloratzp-amilina-tirzepatida-fase2b-resultados-explicados\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T14:46:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-10T07:26:15+00:00\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide\",\"datePublished\":\"2026-10-09T14:46:46+00:00\",\"dateModified\":\"2026-10-10T07:26:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/\"},\"wordCount\":625,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3738.jpg\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/\",\"name\":\"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3738.jpg\",\"datePublished\":\"2026-10-09T14:46:46+00:00\",\"dateModified\":\"2026-10-10T07:26:15+00:00\",\"description\":\"Lilly reported a 48-week phase 2b combination study in 367 adults with type 2 diabetes. Understand the weight results, discontinuations and formulation limits.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3738.jpg\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3738.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Editorial comic illustration: Amylin Meets Tirzepatide. Conceptual cover, not experimental imagery.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/eloratzp-amylin-tirzepatide-phase2b-results-explained\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EloraTZP: Por que pesquisadores est\u00e3o combinando amilina e tirzepatida","description":"A Lilly relatou um estudo de combina\u00e7\u00e3o de fase 2b de 48 semanas em 367 adultos com diabetes tipo 2. Entenda os resultados de peso, descontinua\u00e7\u00f5es e limites de formula\u00e7\u00e3o.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/eloratzp-amilina-tirzepatida-fase2b-resultados-explicados\/","og_locale":"pt_BR","og_type":"article","og_title":"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide","og_description":"Lilly reported a 48-week phase 2b combination study in 367 adults with type 2 diabetes. Understand the weight results, discontinuations and formulation limits.","og_url":"https:\/\/nhdbio.com\/pt-br\/eloratzp-amilina-tirzepatida-fase2b-resultados-explicados\/","og_site_name":"NHD","article_published_time":"2026-10-09T14:46:46+00:00","article_modified_time":"2026-10-10T07:26:15+00:00","author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide","datePublished":"2026-10-09T14:46:46+00:00","dateModified":"2026-10-10T07:26:15+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/"},"wordCount":625,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3738.jpg","articleSection":["Published Study Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/","url":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/","name":"EloraTZP: Por que pesquisadores est\u00e3o combinando amilina e tirzepatida","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3738.jpg","datePublished":"2026-10-09T14:46:46+00:00","dateModified":"2026-10-10T07:26:15+00:00","description":"A Lilly relatou um estudo de combina\u00e7\u00e3o de fase 2b de 48 semanas em 367 adultos com diabetes tipo 2. Entenda os resultados de peso, descontinua\u00e7\u00f5es e limites de formula\u00e7\u00e3o.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3738.jpg","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3738.jpg","width":1536,"height":1024,"caption":"Editorial comic illustration: Amylin Meets Tirzepatide. Conceptual cover, not experimental imagery."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/eloratzp-amylin-tirzepatide-phase2b-results-explained\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"EloraTZP: Why Researchers Are Combining Amylin and Tirzepatide"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe t\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/3738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=3738"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/3738\/revisions"}],"predecessor-version":[{"id":3742,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/3738\/revisions\/3742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/3923"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=3738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=3738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=3738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}